Whole Genome and Exome Sequencing Markets 2021 to 2025 by Research, Clinical, Direct to Consumer, AgriBio and Tumor including Test Price and Volume Forecasts with Executive and Consultant Guides, Including WGS of SARS-CoV-2
April 2021 edition
“Whole Genome Sequencing (WGS) costs plummet and so do prices. Industry on verge of breakout in healthcare, consumer and agricultural markets. The COVID pandemic drives overnight global growth in pathogen sequencing. A new industry emerges.”
The COVID-19 pandemic has created a surge in Whole Genome Sequencing (WGS) of pathogens but cancer-related activity has suffered. Find out all the details in the comprehensive report on the WGS market. The complete genome of the COVID-19 virus is included as an example of the work being done.
- Will all newborns receive Whole Genome Sequencing at birth?
- How fast will Direct to Consumer Testing grow?
- What sequencing technology will take the lead?
- What’s holding the industry back?
- Where are the 800+ locations with high-throughput devices?
A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2025 and includes detailed breakouts for 14 countries and 5 regions.
Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.
Includes supplementary Excel file containing more than 800 locations with high-throughput sequencing instrumentation install base, providing details of systems by name, and number of systems installed.
Subscribe and Save
By signing up for the annual subscription, updates to this report will be automatically provided free of charge for a period of one year from initial purchase. These updates can include revised forecasts as markets increase or contract and exclusive market commentary not seen anywhere else. With the effects of COVID-19 being felt across all markets it has never been more crucial to stay fully informed with real-world actionable data. Subscribe to this report and receive ongoing market forecasting and analysis for sharpened strategic planning throughout the year.
- Quarterly report updates
- Summary of significant developments and market changes
- Phone consultation and assistance on request for the duration of the subscription
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.
All report data is available in Excel format on request with the corporate license.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School